THU0687 THE RISK OF SCHIZOPHRENIA AND EPILEPSY AMONG FAMILIAL MEDITERRANEAN FEVER PATIENTS: A BIG DATABASE ANALYSIS
Authors: Kassem Sharif, Nicola Luigi Bragazzi, Abdulla Watad, Doron Comanesther, Arnon Cohen, Dennis Mcgonagle, Howard Amital
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Several autoimmune diseases have been associated with schizophrenia and epilepsy, however little is known about putative links with the auto-inflammatory conditions. <h3>Objectives:</h3> We investigated the association between familial Mediterranean fever (FMF), a paradigmatic auto-inflammatory disease, schizophrenia and epilepsy, and assessed the impact of the latter disorders on the survival of FMF patients utilizing a large sample database. <h3>Methods:</h3> A case-control study was performed by utilizing the database of Clalit Health Services. FMF patients were compared to age- and sex- matched counterparts in terms of prevalence of schizophrenia and epilepsy. The chi-squared test was used to assess the distribution of categorical variables, while the t-test were applied for continuous variables. Analysis regarding survival were performed using Kaplan-Meier curves, log rank test and multivariate Cox proportional-hazards method. <h3>Results:</h3> The study included 7,747 FMF patients, and 10,080 age- and sex- matched controls. At the univariate analysis, schizophrenia and epilepsy as co-morbidities, 50 FMF patients (0.6%) and 89 controls (0.9%) had schizophrenia, respectively. On multiple logistic regression model, FMF was inversely associated with schizophrenia (OR 0.64 [95%CI 0.43-0.90], p=0.0173), while there was no association between FMF and epilepsy. Subjects having either FMF (HR 1.43 [95%CI 1.23-1.66]), schizophrenia (HR 3.97 [95%CI 1.47- 10.70]) or epilepsy (HR 2.54 [95%CI 1.72-3.75]) were independently associated with all-cause mortality. However, schizophrenia as co-morbidity in FMF subjects did not worsen their prognosis (HR 2.17 [95%CI 0.60-7.86]). <h3>Conclusion:</h3> FMF patients have a significantly lower proportion of schizophrenia than controls. Patients with either FMF, schizophrenia or epilepsy are at higher risk of all-cause mortality<b>,</b> a finding that calls for assessment of better medical management on mortality outcome. <h3>Acknowledgement:</h3> None <h3>Disclosure of Interests:</h3> Kassem Sharif: None declared, Nicola Luigi Bragazzi: None declared, Abdulla Watad: None declared, Doron Comanesther: None declared, Arnon Cohen Grant/research support from: Prof. Arnon Cohen received research grants from Janssen, Novartis and AbbVie and Sanofi, Consultant for: Prof. Arnon Cohen served as a consultant, advisor for AbbVie; Amgen; Boehringer Ingelheim; Dexcel pharma; Janssen, Lilly; Neopharm; Novartis, Perrigo; Pfizer; Rafa; Sanofi , Speakers bureau: Prof. Arnon Cohen served as speaker for AbbVie; Amgen; Boehringer Ingelheim; Dexcel pharma; Janssen, Lilly; Neopharm; Novartis, Perrigo; Pfizer; Rafa; Sanofi , Dennis McGonagle Consultant for: Lilly, Novartis UCB, Speakers bureau: Lilly, Novartis UCB, Howard Amital Grant/research support from: Pfizer, AbbVie, Janssen, Grant/research support from: Pfizer, AbbVie, Janssen, Consultant for: Pfizer, Merck Sharp &amp; Dohme, Consultant for: Pfizer, Merck Sharp &amp; Dohme, Speakers bureau: Pfizer, Merck Sharp &amp; Dohme, Janssen, Sanofi, Bristol-Myers Squibb, Abbvie, Neopharm, Speakers bureau: Pfizer, Merck Sharp &amp; Dohme, Janssen, Sanofi, Bristol-Myers Squibb, Abbvie, Neopharm